Is ICLUSIG (ponatinib) right for you?
ICLUSIG is a TKI medication that may treat adults with Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) for whom previous TKI treatments have stopped working. ICLUSIG may also be considered for adults with CML or Ph+ALL with the T315I mutation. ICLUSIG is not for use to treat people with newly diagnosed chronic phase CML.
Discover how ICLUSIG may help adults with CML and Ph+ ALL regain control
ICLUSIG in CML
Learn more about treatment benefits and risks from clinical studies.
ICLUSIG in Ph+ ALL
Review the efficacy, safety, and more from a clinical study.
Are mutations impacting your treatment?
If you see your BCR-ABL levels rising, a mutation may be to blame.
Meet real patients with CP-CML sharing their stories about treatment with ICLUSIG
"My family has noticed a difference now that I'm taking ICLUSIG"
Watch Matt's story
"ICLUSIG means that I can continue to enjoy life's little pleasures."
Watch Mike's story
Disclaimer: These videos feature real patients sharing their experiences living with CP-CML and being treated with ICLUSIG. The information in these videos is based on their experiences at the time of recording. Given the nature of CP-CML experiences may change over time. These are Mike's and Matt’s experiences while taking ICLUSIG and yours may be different.
*By enrolling in the Takeda Oncology Co-Pay Assistance Program (the “Program”), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:
You must be at least 18 years old, a resident of the United States or a US Territory, and have commercial (private) prescription insurance that does not cover the entire cost of the medication. The Program is not valid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicare, Medicare Advantage, Medigap, Medicaid, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who become eligible for or start using government insurance will no longer be eligible for the Program. The Program is not valid if the entire cost of your prescription is reimbursable by a private insurance plan or other private health or pharmacy benefit programs. You are responsible for reporting receipt of Program assistance to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost, as may be required.
You agree that you will not submit the cost of any portion of the product dispensed pursuant to this Program to a federal or state healthcare program (including, but not limited to, Medicare, Medicare Advantage, Medicaid, TRICARE, VA, DOD, etc.), for purposes of counting it toward your out-of-pocket expenses, and to notify Takeda Oncology Here2Assist® if you become eligible for a federal or state healthcare program. This Program is not conditioned on any past, present or future purchase of any Takeda product, including refills. This Program is valid for 12 months, and your co-pay card may be renewed every 12 months, subject to continued eligibility. This offer is not valid with any other program, discount, or offer involving your prescribed Takeda Oncology medication. This offer may be rescinded, revoked, or amended without notice. No reproductions. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. No income requirements or membership fees. This Program is not health insurance. Cash value of 1/100 of 1¢. For questions about this offer, please contact the Takeda Oncology Co-Pay Assistance Program, a patient support service of Takeda Oncology Here2Assist, at 1-844-817-6468, Option 2, Monday-Friday, 8 AM-8 PM ET.